Core Viewpoint - The company, Dabo Medical, has shown significant growth in its financial performance for the first half of 2025, with notable increases in revenue and profit metrics, despite a slight decline in stock price on August 22, 2025 [1]. Financial Performance - For the first half of 2025, Dabo Medical achieved a revenue of 1.21 billion yuan, representing a year-on-year growth of 25.55% [1]. - The net profit attributable to shareholders reached 244 million yuan, marking a year-on-year increase of 76.69% [1]. - The net profit after deducting non-recurring items was 223 million yuan, reflecting an 82.64% year-on-year growth [1]. - The net cash flow from operating activities was 263 million yuan, which is a 96.3% increase compared to the previous year [1]. - Revenue from overseas business grew by 50.84%, contributing to 13.02% of total revenue [1]. Stock Performance - As of August 22, 2025, Dabo Medical's stock price was 58.41 yuan, down 0.15% from the previous trading day [1]. - The stock opened at 58.75 yuan, reached a high of 58.78 yuan, and a low of 57.51 yuan, with a trading volume of 286 million yuan and a fluctuation of 2.17% [1]. - On August 22, there was a net outflow of 44.22 million yuan in principal funds, accounting for 0.26% of the circulating market value [1]. - Over the past five days, the cumulative net outflow of principal funds was 149 million yuan, representing 0.88% of the circulating market value [1].

Group 1 - The core viewpoint of the news is that Dabo Medical (002901.SZ) has reported its semi-annual results for 2025, highlighting significant institutional investment in the company [1] - As of August 21, 2025, a total of 14 institutional investors hold shares in Dabo Medical, with a combined holding of 192 million shares, representing 46.36% of the total share capital [1] - The top ten institutional investors account for 46.23% of the total shares, with a decrease of 1.08 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one public fund, Southern CSI 1000 ETF, increased its holdings slightly, while six new public funds were disclosed, including Dachen Multi-Strategy Mixed (LOF) A and Dachen Quality Medical Stock A [2] - Three public funds were not disclosed in the current period compared to the previous quarter, including Huabao CSI Medical ETF and Fuyong Medical Health Mixed Fund A [2] - Regarding foreign investment, one foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 0.46% compared to the previous period [2]

大博医疗（SZ 002901，收盘价：58.5元）8月21日晚间发布半年度业绩报告称，2025年上半年营业收入 约12.1亿元，同比增加25.55%；归属于上市公司股东的净利润约2.44亿元，同比增加76.69%；基本每股 收益0.6007元，同比增加79.9%。 （文章来源：每日经济新闻） ...

Financial Performance - The company reported a total revenue of 1.21 billion yuan for the first half of 2025 [1] - The net profit attributable to shareholders was 244 million yuan [1] - The net cash inflow from operating activities was 263 million yuan [1] Key Financial Ratios - The latest debt-to-asset ratio stands at 25.91% [3] - The gross profit margin is reported at 71.01% [3] - The return on equity (ROE) is 7.77% [3] - The diluted earnings per share (EPS) is 0.60 yuan [3] - The total asset turnover ratio is 0.28 times [3] - The inventory turnover ratio is also 0.28 times [3] Shareholder Information - The number of shareholders is approximately 19,400 [3] - The top ten shareholders hold a total of 360 million shares, accounting for 86.93% of the total share capital [3] - The largest shareholder is Guangxi Dabo Business Communication Venture Investment Co., Ltd., holding 23.4% [3]

Core Points - The company held its 18th meeting of the third board of directors on August 21, 2025, where all 7 attending directors approved the resolutions presented [1][2] - The board approved the 2025 semi-annual report and its summary, confirming that the report complies with relevant laws and accurately reflects the company's situation [1][2] - The board also approved a proposal for asset impairment provision, stating that it aligns with accounting standards and the company's policies [2]

证券代码：002901 证券简称：大博医疗 公告编号：2025-032 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）第三届监事会第十七次会议 于 2025 年 8 月 21 日在公司会议室以现场方式召开，会议通知以专人送达、传真、 电子邮件、电话相结合的方式已于 2025 年 8 月 11 日向各位监事发出，本次会议 应参加监事 3 名，实际参加监事 3 名，本次会议的召开符合《公司法》《公司章 程》等法律法规的规定，合法有效。 本次会议由监事会主席詹欢欢女士主持，与会监事就会议议案进行了审议、 表决，形成了如下决议： 二、会议以 3 票同意、0 票反对、0 票弃权的表决结果审议通过《关于计提 资产减值准备的议案》。 经审核，监事会认为：本次计提资产减值准备事项，遵循了谨慎性原则，符 合《企业会计准则》、公司会计政策的规定及公司资产实际情况，该事项的决策 程序合法、依据充分，本次计提资产减值准备事项能够更加公允地反应公司的资 产状况和经营成果。监事会同意公司本次计提资产减值准备。 大博医疗科技股份有限公司 具体内 ...

Core Viewpoint - The report highlights the financial performance and operational status of Double Medical Technology Inc. for the first half of 2025, showcasing significant growth in revenue and net profit, alongside a stable business model in the medical high-value consumables sector. Financial Performance - The company achieved operating revenue of CNY 1,210,439,721.50, representing a year-on-year increase of 25.55% compared to CNY 964,129,205.76 in the same period last year [2][10]. - The net profit attributable to shareholders reached CNY 244,258,762.40, up 76.69% from the previous year, while the net profit after deducting non-recurring gains and losses was CNY 222,695,524.72, reflecting an increase of 82.64% [2][10]. - The basic earnings per share increased by 79.90% to CNY 0.6007 from CNY 0.3339 [2][10]. - The overall gross margin for the reporting period was 71.01% [10]. Business Overview - The main business of the company involves the production, research, and sales of medical high-value consumables, including orthopedic trauma implants, spinal implants, joint implants, sports medicine, and minimally invasive surgical consumables [3][4]. - The company’s product lines showed collaborative growth, with trauma products generating CNY 468,220,039.78 in revenue, a 23.68% increase, and spinal products achieving CNY 217,257,515.06, up 29.86% [10][11]. International Expansion - The company has been actively expanding its international market presence, with products exported to over 70 countries, including Australia, Ukraine, and Chile. The overseas business revenue reached CNY 157,583,735.84, marking a 50.84% increase [11][12]. R&D and Quality Management - The company has established a comprehensive R&D system, holding 110 invention patents and 251 medical device registration certificates, with some products certified by FDA and CE [12][14]. - A strict quality management system is in place to ensure product reliability and safety, which is critical for maintaining the company's reputation in the medical field [14]. Marketing and Sales Strategy - The company employs a distribution-focused sales model, supported by a robust marketing network across more than 30 provinces in China, enhancing its market influence and brand recognition [15][16]. - The marketing strategy includes training programs for distributors and direct engagement with healthcare professionals to promote product awareness and usage [10][11].

| | | 大博医疗科技股份有限公司2025年半年度报 | | | --- | --- | --- | --- | | 告摘要 | | | | | 证券代码：002901 证券简称：大博医疗 | | | 公告 | | 编号：2025-029 | | | | | 大博医疗科技股份有限公司 2025 年半年度报告摘要 | | | | | 一、重要提示 | | | | | 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 | | | | | 资者应当到证监会 | | | | | 指定媒体仔细阅读半年度报告全文。 | | | | | 所有董事均已出席了审议本报告的董事会会议。 | | | | | 非标准审计意见提示 | | | | | □适用 √ 不适用 | | | | | 董事会审议的报告期利润分配预案或公积金转增股本预案 | | | | | √ □适用 不适用 | | | | | 公司计划不派发现金红利，不送红股，不以公积金转增股本。 | | | | | 董事会决议通过的本报告期优先股利润分配预案 | | | | | □适用 √ 不适用 | | | | | 二、公司基本情 ...

Group 1 - The core viewpoint of the article is that Dabo Medical (002901.SZ) has shown significant growth in its financial performance for the first half of 2025, with notable increases in both revenue and net profit [1] - The company's operating revenue reached 1.21 billion yuan, representing a year-on-year growth of 25.55% [1] - The net profit attributable to shareholders of the listed company was 244 million yuan, reflecting a year-on-year increase of 76.69% [1] Group 2 - The net profit attributable to shareholders after deducting non-recurring gains and losses was 223 million yuan, which is an increase of 82.64% year-on-year [1] - The basic earnings per share for the company stood at 0.6007 yuan [1]

Company Overview - Dabo Medical focuses on the research, production, and sales of high-value consumables for orthopedic implants, covering trauma, spine, and joint fields [1]. Financial Performance - For the first half of 2025, Dabo Medical reported a revenue of 1.21 billion yuan, representing a year-on-year growth of 25.55% [1]. - The net profit attributable to shareholders reached 244 million yuan, showing a significant increase of 76.69% year-on-year [1]. - Revenue from trauma products was 468 million yuan, up 23.68% year-on-year, while spine product revenue was 217 million yuan, reflecting a growth of 29.86% [1]. Market Activity - As of August 21, 2025, Dabo Medical's stock price closed at 58.50 yuan, down 0.37% from the previous trading day [1]. - The trading volume for the day was 270 million yuan, with a price fluctuation of 1.87% [1]. - On August 21, the net inflow of main funds was 9.74 million yuan, while the net outflow over the past five days totaled 112 million yuan [1].